AD/PD™ Alzheimer’s & Parkinson’s Diseases Conference 2025

Spear Bio at the 2025 AD/PD™ Conference: Advancing Alzheimer’s & Parkinson’s Disease Research

Spear Bio is excited to sponsor the 2025 AD/PD™ Alzheimer’s & Parkinson’s Diseases Conference in Vienna, Austria, from April 1-5. In addition, we’re showcasing our latest innovations to help researchers make breakthroughs in these challenging diseases.

Revolutionizing Biomarker Research with SPEAR Technology

Poster Title:
Ultra-Sensitive Differentiation of p-Tau 217 in MCI and Dementia Patients: Comparing Amyloid PET Negative and Positive Results

Authors: Tsz Wing Fan, PhD, Corinne Thomas, PhD, WonHee Kim, PhD, Wenjing Jiang, MS, Jeremy Tan, MS and Feng Xuan, PhD, SPEAR BIO INC, Woburn, MA, USA

Presenter: Corinne Thomas, PhD – April 4-5, 2025

Research on neurodegenerative blood-based biomarkers requires fg/mL sensitivity to overcome blood-brain barrier dilution. Current ultra-sensitive technologies need large sample volumes, high-affinity antibodies, immobilization of reagents, and stringent washing, relying on proprietary instrumentation, which limits frequent monitoring and large-scale screening. This highlights the need for a scalable ultra-sensitive solution.

Plasma pTau217 has shown high diagnostic accuracy for detecting Alzheimer’s disease (AD) amyloid pathology, with promise as a standalone biomarker and confirmatory test for amyloid-targeting therapies in patients with mild cognitive impairment or dementia. However, to align with FDA-approved CSF biomarker tests or amyloid PET for AD, amyloid assays need a positive predictive value (PPV) of 90% to 95% and at least 90% accuracy.

A scalable, ultra-sensitive pTau217 assay with these specifications would address the growing demand for reliable blood-based biomarkers in AD diagnosis and treatment, supporting broader clinical and research use.

Unlock Ultra-Sensitive Detection for Alzheimer’s & Parkinson’s Disease Biomarkers

SPEAR Technology provides a scalable, ultra-sensitive approach to detecting low-abundant blood-based biomarkers in Alzheimer’s & Parkinson’s Disease research. In particular, our solution enables researchers to quantify biomarkers at sub fg/mL levels from just sub-µL samples, providing unparalleled sensitivity.

Detect Hard-to-Measure Neurological Biomarkers with Ease

SPEAR Technology excels in detecting biomarkers such as NfL, pTau 217, pTau 231, and other critical neurological markers. Because of its sensitivity, our technology makes it easier to measure and discern these biomarkers, which are often challenging to quantify in plasma and serum as a result of their low abundance. This capability directly supports progress in Alzheimer’s & Parkinson’s Disease research.

Empowering Researchers to Advance Alzheimer’s & Parkinson’s Disease Understanding

By improving accessibility to ultra-sensitive immunoassays, we empower more researchers to dive deeper into the complexities of Alzheimer’s & Parkinson’s Disease. Ultimately, our technology helps accelerate discoveries, paving the way for innovative treatments.

Join Us at the 2025 AD/PD™ Alzheimer’s & Parkinson’s Disease Conference to Learn More

Don’t miss the opportunity to speak with our team at the 2025 AD/PD™ conference. We’ll be there to discuss how SPEAR Technology is enabling the next generation of Alzheimer’s & Parkinson’s Disease research and driving progress toward better diagnostics and therapies.

To learn more about applications of Spear Bio assays for studying Alzheimer’s & Parkinson’s Diseases, visit our resources section or subscribe to our newsletter. Either way, you can easily download our related app notes and access valuable insights that will enhance your research.